Trial Profile
Seven-Hundred and Fifty Patients Treated with Rituximab for RA in European Registries: Baseline Data Analysis from the Collaborative European REgistries for Rituximab in RA (CERERRA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms CERERRA
- 15 Jan 2017 Results of Rituximab Retreatment (n=800), published in The Journal of Rheumatology
- 28 Nov 2008 New trial record.